[Federal Register Volume 90, Number 122 (Friday, June 27, 2025)]
[Notices]
[Pages 27540-27542]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-11980]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[Document Identifiers: CMS-10328 and CMS-10148]


Agency Information Collection Activities: Proposed Collection; 
Comment Request

AGENCY: Centers for Medicare & Medicaid Services, Health and Human 
Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Centers for Medicare & Medicaid Services (CMS) is 
announcing an opportunity for the public to comment on CMS' intention 
to collect information from the public. Under the Paperwork Reduction 
Act of 1995 (PRA), federal agencies are required to publish notice in 
the Federal Register concerning each proposed collection of information 
(including each proposed extension or reinstatement of an existing

[[Page 27541]]

collection of information) and to allow 60 days for public comment on 
the proposed action. Interested persons are invited to send comments 
regarding our burden estimates or any other aspect of this collection 
of information, including the necessity and utility of the proposed 
information collection for the proper performance of the agency's 
functions, the accuracy of the estimated burden, ways to enhance the 
quality, utility, and clarity of the information to be collected, and 
the use of automated collection techniques or other forms of 
information technology to minimize the information collection burden.

DATES: Comments must be received by August 26, 2025.

ADDRESSES: When commenting, please reference the document identifier or 
OMB control number. To be assured consideration, comments and 
recommendations must be submitted in any one of the following ways:
    1. Electronically. You may send your comments electronically to 
http://www.regulations.gov. Follow the instructions for ``Comment or 
Submission'' or ``More Search Options'' to find the information 
collection document(s) that are accepting comments.
    2. By regular mail. You may mail written comments to the following 
address: CMS, Office of Strategic Operations and Regulatory Affairs, 
Division of Regulations Development, Attention: Document Identifier/OMB 
Control Number: __, Room C4-26-05, 7500 Security Boulevard, Baltimore, 
Maryland 21244-1850.
    To obtain copies of a supporting statement and any related forms 
for the proposed collection(s) summarized in this notice, please access 
the CMS PRA website by copying and pasting the following web address 
into your web browser: https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing.

FOR FURTHER INFORMATION CONTACT: William N. Parham at (410) 786-4669.

SUPPLEMENTARY INFORMATION: 

Contents

    This notice sets out a summary of the use and burden associated 
with the following information collections. More detailed information 
can be found in each collection's supporting statement and associated 
materials (see ADDRESSES).

CMS-10328 Medicare Self-Referral Disclosure Protocol
CMS-10148 HIPAA Administrative Simplification (Non-Privacy/Security) 
Complaint Form

    Under the PRA (44 U.S.C. 3501-3520), federal agencies must obtain 
approval from the Office of Management and Budget (OMB) for each 
collection of information they conduct or sponsor. The term 
``collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 
1320.3(c) and includes agency requests or requirements that members of 
the public submit reports, keep records, or provide information to a 
third party. Section 3506(c)(2)(A) of the PRA requires federal agencies 
to publish a 60-day notice in the Federal Register concerning each 
proposed collection of information, including each proposed extension 
or reinstatement of an existing collection of information, before 
submitting the collection to OMB for approval. To comply with this 
requirement, CMS is publishing this notice.

Information Collections

    1. Type of Information Collection Request: Revision of a currently 
approved collection; Title of Information Collection: Medicare Self-
Referral Disclosure Protocol; Use: Section 6409 of the ACA requires the 
Secretary to establish a voluntary self-disclosure process that allows 
providers of services and suppliers to self-disclose actual or 
potential violations of section 1877 of the Act. The SRDP is a 
voluntary self-disclosure process that allows providers of services and 
suppliers to disclose actual or potential violations of section 1877 of 
the Act. For purposes of the SRDP, a person submitting a disclosure to 
the SRDP will be referred to as a ``disclosing party.'' CMS analyzes 
the disclosed conduct to determine compliance with section 1877 of the 
Act and the application of the exceptions to the physician self-
referral prohibition.
    Specifically, under the proposal a physician practice disclosing 
group practice noncompliance will submit an SRDP form consisting of the 
following components: (1) the SRDP Disclosure Form, (2) a single Group 
Practice Information Form covering all the physicians in the practice 
who made prohibited referrals to the practice, and (3) a Financial 
Analysis Worksheet. All other entities will continue to submit 
disclosures using the SRDP Disclosure Form, separate Physician 
Information Forms for each physician covered in the self-disclosure, 
and a Financial Analysis Worksheet. Form Number: CMS-10328 (OMB control 
number: 0938-1106); Frequency: Yearly; Affected Public: Private Sector 
(Business or other for-profits, Not-for-Profit Institutions); Number of 
Respondents: 100; Total Annual Responses: 100; Total Annual Hours: 
4,950. (For policy questions regarding this collection contact Caitlin 
Bailey at 410-786-9768.)
    2. Type of Information Collection Request: Revision of a currently 
approved collection; Title of Information Collection: HIPAA 
Administrative Simplification (Non-Privacy/Security) Complaint Form; 
Use: The Secretary of Health and Human Services (HHS), hereafter known 
as ``The Secretary,'' codified 45 CFR parts 160 and 164 Administrative 
Simplification provisions that apply to the enforcement of the Health 
Insurance Portability and Accountability Act of 1996 Public Law 104-191 
(HIPAA). The provisions address rules relating to the investigation of 
non-compliance of the HIPAA Administrative Simplification code sets, 
unique identifiers, operating rules, and transactions. 45 CFR 160.306, 
Complaints to the Secretary, provides for investigations of covered 
entities by the Secretary. Further, it outlines the procedures and 
requirements for filing a complaint against a covered entity.
    Anyone can file a complaint if he or she suspects a potential 
violation. Persons believing that a covered entity is not utilizing the 
adopted Administrative Simplification provisions of HIPAA are 
voluntarily requested to file a complaint with CMS via the 
Administrative Simplification Enforcement and Testing Tool (ASETT) 
online system, by mail, or by sending an email to the HIPAA mailbox at 
[email protected]. Information provided on the standard form 
will be used during the investigation process to validate non-
compliance of HIPAA Administrative Simplification provisions.
    This standard form collects identifying and contact information of 
the complainant, as well as the identifying and contact information of 
the filed against entity (FAE). This information enables CMS to respond 
to the complainant and gather more information if necessary, and to 
contact the FAE to discuss the complaint and CMS' findings. Form 
Number: CMS-10148 (OMB control number: 0938-0948); Frequency: 
Occasionally; Affected Public: Private sector, Business or Not-for-
profit institutions, State, Local, or Tribal Governments, Federal 
Government, Not-for-profits institutions; Number of Respondents: 400; 
Total Annual Responses: 400; Total Annual Hours: 400. (For policy 
questions regarding this collection contact Kevin Stewart at 410-786-
6149).
    3. Type of Information Collection Request: Revision of a currently 
approved collection; Title of Information Collection: Drug Price

[[Page 27542]]

Negotiation for Initial Price Applicability Year 2028 under Sections 
11001 and 11002 of the Inflation Reduction Act Information Collection 
Request (ICR) (CMS-10849, OMB 0938-1452); Use: Under the authority in 
sections 11001 and 11002 of the Inflation Reduction Act of 2022 (Pub. 
L. 117-169), the Centers for Medicare & Medicaid Services (CMS) is 
implementing the Medicare Drug Price Negotiation Program, codified in 
sections 1191 through 1198 of the Social Security Act (``the Act''). 
The Act establishes the Negotiation Program to negotiate maximum fair 
prices (``MFPs''), defined at 1191(c)(3) of the Act, for certain high 
expenditure, single source selected drugs covered under Medicare Part B 
and Part D. For the third cycle of the Negotiation Program, the 
Secretary of Health and Human Services (the ``Secretary'') will select 
up to 15 high expenditure, single source drugs payable under Part B 
and/or covered under Part D for negotiation. In accordance with section 
1194(f)(4) of the Act, CMS will also renegotiate MFPs for drugs 
selected for renegotiation, if any, for initial price applicability 
year 2028.
    Negotiation Data Elements: The statute requires that CMS consider 
certain data from Primary Manufacturers as part of the negotiation 
process. To the extent that more than one entity meets the statutory 
definition of manufacturer (specified in section 1193(a)(1) of the Act) 
for a selected drug for purposes of initial price applicability year 
2028, CMS will designate the entity that holds the New Drug 
Application(s) (NDA(s))/Biologics License Application(s) (BLA(s)) for 
the selected drug to be ``the manufacturer'' of the selected drug 
(hereinafter the ``Primary Manufacturer''). The Primary Manufacturer's 
data submissions include the non-Federal average manufacturer price and 
related data for selected drugs for the purpose of establishing a 
ceiling price, as outlined in section 1193(a)(4)(A) of the Act, and 
information that the Secretary requires, pertaining to the negotiation 
factors outlined in section 1194(e)(1) of the Act, for the purpose of 
formulating offers and counteroffers pursuant to section 1193(a)(4)(B) 
of the Act. Some of these data are held by the Primary Manufacturer and 
are not currently available to CMS. Data described in sections 
1194(e)(1) and 1193(a)(4) of the Act must be submitted by the Primary 
Manufacturer.
    Section 1194(e)(2) of the Act requires CMS to consider certain data 
on selected drugs and their alternative treatments. Because the statute 
does not specify where these data come from, CMS will allow for 
optional submission from Primary Manufacturers and the public for drugs 
selected for negotiation or renegotiation. CMS will additionally review 
existing literature, conduct internal analyses, and consult subject 
matter and clinical experts on the factors listed in section 1194(e)(2) 
of the Act. Manufacturers may optionally submit this information as 
part of their Negotiation Data Elements Information Collection Request 
Form. The public may also optionally submit evidence about the selected 
drugs and their alternative treatments.
    Drug Price Negotiation and Renegotiation Process: Any MFPs that are 
negotiated or renegotiated for these selected drugs will apply 
beginning in initial price applicability year 2028. For initial price 
applicability year 2028, the negotiation and renegotiation period 
begins on the earlier of the date that the Primary Manufacturer enters 
into a Medicare Drug Price Negotiation Program Agreement or February 
28, 2026.
    Section 1194(b)(2)(C) of the Act provides that if the Primary 
Manufacturer does not accept CMS' written initial offer, the Primary 
Manufacturer may submit an optional written counteroffer no later than 
30 days after the date of receipt of CMS' written initial offer. If the 
Primary Manufacturer chooses to develop and submit a written 
counteroffer to CMS' written initial offer during the drug price 
negotiation or renegotiation process for initial price applicability 
year 2028, the Primary Manufacturer must submit the Counteroffer Form. 
Form Number: CMS-10849 (OMB control number: 0938-1452); Frequency: 
Once; Affected Public: Private sector, Business or other for-profit; 
Number of Respondents: 405; Number of Responses: 405; Total Annual 
Hours: 51,940. (For questions regarding this collection, contact 
Elisabeth Daniel at 667-290-8793.)

William N. Parham, III,
Director, Division of Information Collections and Regulatory Impacts, 
Office of Strategic Operations and Regulatory Affairs.
[FR Doc. 2025-11980 Filed 6-26-25; 8:45 am]
BILLING CODE 4120-01-P